News

MHRP’s molecular epidemiologists played a key role on a research team that analyzed the HIV-1 genome sequences from infected volunteers in the Step HIV vaccine trial. Findings indicate that that although ineffective at preventing infection, the vaccine impacted the genetic makeup of the virus that infected the volunteers. Results were published Feb. 27 in Nature Medicine.

After...

In Southwestern Tanzania, just steps from the Malawi border lies the bustling port town of Kyela, one of eight districts in the Mbeya region. A bustling commercial hub, Kyela endures an HIV prevalence rate well above the national average, which leaves a staggering number of children orphaned and vulnerable. In Kyela, approximately 7,100 children have been orphaned following the devastating...

MHRP scientists have identified three highly effective, non-proprietary and easily manufactured adjuvants that proved safe and more potent than a widely used adjuvant in commercial vaccines for inducing antibodies to anthrax protective antigen. Adjuvants are vaccine components designed to stimulate the immune system, therefore enhancing the body’s ability to protect against diseases. The study...

MHRP scientists have developed a monoclonal antibody that binds solely to lipids located inside cells but has the capability to neutralize HIV.  This research is published in the October 26, 2010 online issue of Biochemical and Biophysical Research Communications.

Investigators compared WR321, a non-human monoclonal IgG antibody that binds to phosphoinositide lipids, developed by Dr....